NLS Denmark

Zealand Pharma has signed an exclusive license agreement with newly formed US biopharmaceutical company Elvinix, granting the rights to develop and commercialize a GLP-1/gastrin dual-agonist peptide portfolio as a regenerative therapy for type 1 diabetes.

Quantum Foundry Copenhagen and the Novo Nordisk Foundation are building a 5,300m² quantum chip fabrication facility in Copenhagen, aiming to strengthen Europe's position in the global quantum race.

Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.

A broad coalition of partners is establishing an association to support the long-term and sustainable development of the district.

The Novo Nordisk Foundation has allocated up to EUR 736 million to BioInnovation Institute (BII).

The Japanese start-up QunaSys has chose to locate their European headquarters in Innovation District Copenhagen, in the start-up community Quantum Denmark.